Welcome to our dedicated page for Envoy Medical news (Ticker: COCH), a resource for investors and traders seeking the latest updates and insights on Envoy Medical stock.
Envoy Medical, Inc. develops hearing-health technologies focused on fully implanted hearing solutions. The company’s portfolio includes the Esteem FI-AMEI, an FDA-approved fully implanted active middle ear implant for adults with moderate to severe sensorineural hearing loss, and the investigational Acclaim cochlear implant, which uses a sensor designed to work with the ear’s natural anatomy rather than an external microphone.
Recurring company news covers Acclaim clinical-study updates, FDA-related development toward a Premarket Approval pathway, financial results, capital-structure actions, Nasdaq listing compliance, board and governance changes, and intellectual-property updates tied to its hearing segment.
Envoy Medical (NASDAQ: COCH), a hearing health company focused on fully implanted hearing devices, has secured a $10 million lending facility from long-time investor and majority shareholder Glen Taylor. The company has already drawn $5 million from this facility. The five-year, unsecured loan defers interest for the first two years and carries an 8% interest rate.
Envoy Medical plans to seek an Investigational Device Exemption (IDE) for its fully implanted Acclaim® cochlear implant, aiming to start a Pivotal Study in late 2024 or early 2025. The company also has the FDA-approved Esteem® device, the only fully implanted active middle ear implant on the market. Envoy Medical is working with Congress to reclassify fully implanted active middle ear implants, potentially improving patient access and encouraging innovation in the hearing implant category.
Envoy Medical (Nasdaq: COCH) reports Q2 2024 results and provides a business update on its fully implanted Acclaim® cochlear implant. Key highlights include:
1. Early Feasibility Study (EFS) at Mayo Clinic shows promising results with three participants completing 18-month follow-ups.
2. The company has addressed system noise issues and implemented improvements.
3. Envoy Medical aims to submit an IDE application for a Pivotal Clinical Trial in the coming months, with potential enrollment by year-end 2024.
4. Q2 2024 revenue was $68,000, up from $63,000 in Q2 2023.
5. R&D expenses increased to $2.6 million, while G&A expenses decreased to $1.6 million.
6. Cash and cash equivalents stood at $1.7 million as of June 30, 2024.
Envoy Medical announced its support for the bipartisan Senate bill, the Hearing Device Coverage Clarification Act (S.4829), introduced on July 29, 2024. The bill aims to classify implanted active middle ear hearing devices as prosthetics, making them eligible for Medicare coverage. Currently, these devices are excluded under the hearing aid category. The legislation was introduced by Senators Amy Klobuchar and James Lankford and is expected to receive additional bipartisan support. Envoy Medical’s CEO, Brent Lucas, emphasized that the bill's passage will benefit patients with significant hearing loss, foster competition and innovation, and create more jobs. Envoy Medical is notable for its FDA-approved Esteem® Fully Implanted Active Middle Ear Hearing Device, the only fully implanted device of its kind.
Envoy Medical, a company specializing in fully implanted hearing systems, has announced that its shares have been selected for inclusion in the Russell Microcap Index. This inclusion took effect at the close of the market on June 28, 2024. The Russell Microcap Index tracks the performance of the microcap segment in the US equity market, and various microcap ETFs are expected to adjust their holdings accordingly. Envoy Medical's CEO, Brent Lucas, highlighted that this inclusion is a significant step in raising awareness about the company and its growth potential in the hearing technology sector.
Envoy Medical announced the appointment of Michael Crowe to its Board of Directors, effective June 7, 2024. Crowe brings decades of experience in scaling operations in the medical device industry, having previously worked at General Electric, Johnson & Johnson, Covidien Surgical Devices, and Abbott Vascular. He is currently the Senior VP of Operations at Bioventus. Envoy Medical is sponsoring an Early Feasibility Study at Mayo Clinic for its Acclaim Cochlear Implant, with plans for a pivotal clinical study later in 2024. Crowe will serve on the Compensation Committee, replacing Dr. Whitney Haring-Smith. The company aims to leverage Crowe's expertise for its growth and market disruption plans.
Envoy Medical has announced the inclusion of its shares in the MSCI USA Micro Cap Index, effective from the close of market on May 31, 2024. This inclusion signifies the company's entry into a prestigious index that tracks the performance of the U.S. micro-cap segment, comprising over 1,100 constituents with an average market cap of $122 million as of April 30, 2024.
The MSCI USA Micro Cap Index is a key benchmark for microcap ETFs, and its changes could influence the reweighting of these ETFs' holdings in the coming weeks. Envoy Medical, traded under the ticker COCH on Nasdaq, focuses on fully implanted hearing systems, positioning itself as a revolutionary player in the hearing health industry.
Envoy Medical (Nasdaq: COCH) has highlighted a peer-reviewed article in Current Otorhinolaryngology Reports discussing advancements in fully implanted cochlear implants (FICI). The article, authored by Mayo Clinic doctors, reviews the current state of FICI, including challenges and breakthroughs. It emphasizes the influence of middle ear implants (MEIs) on FICI development, particularly microphone technologies that bypass external microphones. Envoy Medical’s Esteem® device is currently the only commercially available fully implanted active middle ear implant. CEO Brent T. Lucas underscores the benefits of leveraging outer and middle ear anatomy for better integration with accessories like headphones. The article also highlights the importance of a well-designed implantable power supply, noting Envoy Medical’s choice of a larger rechargeable battery in the pectoral region for its investigational Acclaim® cochlear implant.
Envoy Medical (Nasdaq: COCH) reported its Q1 2024 results, highlighting progress in its fully implanted cochlear implant development. All three participants in the Early Feasibility Study (EFS) at Mayo Clinic completed their 12-month follow-ups and continue using their devices daily. The company plans to file an Investigational Device Exemption (IDE) application for a pivotal clinical trial later in 2024 but has converted the current IDE application to a pre-submission for additional data collection and discussions with the FDA.
Financially, Envoy Medical reported revenue of $59K, down from $78K in Q1 2023. R&D expenses increased by $0.4M due to higher personnel costs. Sales and marketing expenses decreased by $46K, while general and administrative expenses rose by $0.7M. The company secured a $10M lending facility from investor Glen Taylor, with $5M drawn initially. Cash and cash equivalents stood at $4.9M as of March 31, 2024.
Summary not available.
Summary not available.